View Financial HealthPHC Holdings 배당 및 자사주 매입배당 기준 점검 2/6PHC Holdings 은(는) 현재 수익률이 3.92% 인 배당금 지급 회사입니다.핵심 정보3.9%배당 수익률-0.007%자사주 매입 수익률총 주주 수익률3.9%미래 배당 수익률4.1%배당 성장률-7.7%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향150%최근 배당 및 자사주 매입 업데이트공시 • Nov 12+ 1 more updatePHC Holdings Corporation Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2026, Payable on December 18, 2025PHC Holdings Corporation announced dividend for the second quarter end of the fiscal year ending March 31, 2026. For the period, the company announced dividend of JPY 21.00 per share against JPY 21.00 per share a year ago. Scheduled date to commence dividend payments: December 18, 2025.모든 업데이트 보기Recent updates공시 • May 14PHC Holdings Corporation, Annual General Meeting, Jun 24, 2026PHC Holdings Corporation, Annual General Meeting, Jun 24, 2026.공시 • Apr 03PHC Holdings Corporation to Report Fiscal Year 2026 Results on May 13, 2026PHC Holdings Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 13, 2026공시 • Jan 02Phc Holdings Corporation Announces Resignation of Koichiro Sato as Senior Executive Vice President, Representative Director and Chief Operating Officer, Effective January 2, 2026On December 31, 2025 (the “Execution Date”), Senseonics Holdings Inc. (the “Company”), Senseonics, Incorporated, a wholly-owned subsidiary of the Company (“Senseonics Inc.” and together with the Company, the “Purchaser Parties”) and Ascensia Diabetes Care Holdings AG (the “Seller”) entered into a master asset purchase agreement (the “Master Asset Purchase Agreement”), pursuant to which, among other things, the Purchaser Parties agreed to acquire Seller’s and as applicable, Seller’s affiliates’, right, title and interest in and to certain assets related Seller’s marketing, selling and distribution of the Eversense® product in the United States (such assets, the “U.S. Purchased Assets”). Pursuant to the terms of the Master Asset Purchase Agreement, the Purchaser Parties agreed to assume certain liabilities and obligations associated with the U.S. Purchased Assets (the “U.S. Assumed Liabilities” and together with the U.S. Purchased Assets, the “U.S. Asset Purchase”), including, but not limited to, certain liabilities under the contracts transferred to the Purchaser Parties under the Master Asset Purchase Agreement, liabilities arising out of the use or ownership of the transferred assets after the closing, and liabilities and obligations arising from certain employees whose employment is transferred to Senseonics Inc. pursuant to new employment letter agreements with Senseonics Inc. The U.S. Asset Purchase closed on January 1, 2026 (the “U.S. Closing”). On the Execution Date, in connection with the transactions described in Item 1.01 of this report, Koichiro Sato, Senior Executive Vice President, Representative Director and Chief Operating Officer of PHC Holdings Corporation, the parent company of the Seller, notified the board of directors (the “Board”) of the Company of his resignation from the Board effective immediately. Mr. Sato’s resignation is not due to any disagreements with the Company, management or Board on any matter relating to the Company’s operations, policies, or practices.공시 • Dec 02PHC Holdings Corporation to Report Q3, 2026 Results on Feb 12, 2026PHC Holdings Corporation announced that they will report Q3, 2026 results on Feb 12, 2026공시 • Nov 12+ 1 more updatePHC Holdings Corporation Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2026, Payable on December 18, 2025PHC Holdings Corporation announced dividend for the second quarter end of the fiscal year ending March 31, 2026. For the period, the company announced dividend of JPY 21.00 per share against JPY 21.00 per share a year ago. Scheduled date to commence dividend payments: December 18, 2025.공시 • Sep 04PHC Holdings Corporation to Report Q2, 2026 Results on Nov 12, 2025PHC Holdings Corporation announced that they will report Q2, 2026 results on Nov 12, 2025공시 • May 31PHC Holdings Corporation to Report Q1, 2026 Results on Aug 07, 2025PHC Holdings Corporation announced that they will report Q1, 2026 results on Aug 07, 2025공시 • May 13PHC Holdings Corporation, Annual General Meeting, Jun 25, 2025PHC Holdings Corporation, Annual General Meeting, Jun 25, 2025.공시 • Mar 07PHC Holdings Corporation to Report Fiscal Year 2025 Results on May 13, 2025PHC Holdings Corporation announced that they will report fiscal year 2025 results on May 13, 2025공시 • Dec 06PHC Holdings Corporation to Report Q3, 2025 Results on Feb 12, 2025PHC Holdings Corporation announced that they will report Q3, 2025 results on Feb 12, 2025공시 • Sep 04+ 1 more updatePHC Holdings Corporation to Report Q2, 2025 Results on Nov 13, 2024PHC Holdings Corporation announced that they will report Q2, 2025 results on Nov 13, 2024공시 • Aug 30Phc Unveils Prototype of Licellgrow, New Cell Expansion System to Support Development of Cell and Gene Therapy Products Manufacturing ProcessPHC Corporation Biomedical Division will showcase a prototype of its new cell expansion system LiCellGrow at the ISCT (International Society for Cell & Gene Therapy) Europe 2024 Regional Meeting held in Gothenburg, Sweden on September 4-6. LiCellGrow, currently under development, is designed to allow pharmaceutical companies to visualize continuous metabolic changes in cells in real-time and adjust the cell culture automatically to optimize conditions for cell growth. The system seeks to expand availability of cell and gene therapy products by accelerating the manufacturing of specific cells needed for these therapies. CGT, in which a patient’s cells are removed, modified, and reintroduced to the body to fight disease, has emerged as a promising therapeutic field for difficult-to-treat conditions such as cancers and hematologic disorders. Since the patient’s own cells are used as raw materials, it is essential to maintain stable cell quality when producing new cells, to counteract natural variations in cell characteristics and ensure consistency throughout the therapy manufacturing process. The current method of evaluating cell quality by sampling the final product may lower both manufacturing efficiency and yield, increasing production cost. LiCellGrow seeks to enable more efficient and stable manufacture of high-quality CGT products by enabling researchers to monitor and control the cell culture environment in real time, optimizing cell quality while minimizing interruption to the therapy manufacturing process. The system under development uses proprietary In-Line monitoring technology, which continuously measures cell metabolites in the culture medium without the need for repeated sampling by immersing sensors in the medium at all times. LiCellGrow then continuously and accurately measures concentrations of two critical indicators of cell metabolism, glucose and lactate, to offer a visualization of actual changes in the culture environment and cell status. Based on real-time measurement data, the system then automatically exchanges the culture medium to maintain the culture environment in an optimal state. This technology is designed to improve and homogenize cell quality while increasing cell culture efficiency and reducing costs through loss reduction. The system will also feature easy-to-install single-use culture bags with In-Line sensors, enabling closed-system cell culturing to maintain a sterile environment, and can be installed in existing CO2 incubators, enabling researchers to conduct studies using their preferred equipment. LiCellGrow is an example of synergy between the Biomedical Division and IVD Division of PHC Corporation. The In-Line monitoring technology featured in this cell expansion system is newly developed proprietary technology building on the core technology of blood glucose sensor, the main product developed by IVD. By combining this sensor technology from IVD with advanced cell culture environment control technology from the Biomedical Division, PHC seeks to offer researchers and pharmaceutical companies greater value. The Biomedical Division plans to launch LiCellGrow to support the development of manufacturing processes for CGT products globally in the short term, and aims to accelerate development of this system to ultimately support commercialized production of CGT products. LiCellGrow builds on the Biomedical Division’s 20-year history of pioneering solutions in the field of cell therapy, including the Cell Processing Center in 2000 and the Cell Processing Isolator in 2007. Moving forward, they will continue to accelerate the creation of innovative solutions addressing QCD challenges in the therapeutic manufacturing process for early adoption of CGT, aiming to contribute to advancing modalities.공시 • Jun 28PHC Holdings Corporation to Report Q1, 2025 Results on Aug 08, 2024PHC Holdings Corporation announced that they will report Q1, 2025 results on Aug 08, 2024공시 • May 12PHC Holdings Corporation, Annual General Meeting, Jun 26, 2024PHC Holdings Corporation, Annual General Meeting, Jun 26, 2024.공시 • Mar 09PHC Holdings Corporation to Report Fiscal Year 2024 Results on May 10, 2024PHC Holdings Corporation announced that they will report fiscal year 2024 results on May 10, 2024공시 • Feb 13+ 1 more updatePHC Holdings Co., Ltd. Announces Management ChangesPHC Holdings Co. Ltd. has decided that Kyoko Deguchi will be appointed as the company's representative director and president on April 1, 2024. Masatsugu Miyazaki will step down from his duties as Representative director and president on March 31, and will continue to serve as a director until the general meeting of shareholders to be held in June. Mr. Deguchi, who is currently an independent director of the Company, has over 20 years of experience in the healthcare and chemical industries, and has previously served as head of the Japanese subsidiary of various global healthcare companies, including Janssen Pharmaceuticals, Stryker, and AbbVie. He has held senior positions in finance, marketing, etc. Currently, he is involved in management as the vice director of rehabilitation orthopedics, and has experience as an outside director at multiple listed and unlisted companies, including T-Gaia Co. Ltd. and Heartseed Co. Ltd.공시 • Dec 09PHC Holdings Corporation to Report Q3, 2024 Results on Feb 09, 2024PHC Holdings Corporation announced that they will report Q3, 2024 results on Feb 09, 2024공시 • Aug 30PHC Holdings Corporation to Report Q2, 2024 Results on Nov 10, 2023PHC Holdings Corporation announced that they will report Q2, 2024 results on Nov 10, 2023공시 • Jul 11Bio-Techne Corporation (NasdaqGS:TECH) acquired Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others.Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others on June 22, 2023. The transaction is expected to complete in first quarter of fiscal year 2024. Wenger Plattner acted as legal advisor to Bio-Techne. Bourgeois Avocat SA acted as legal advisor and UBS Investment Bank acted as financial advisor to Lunaphore Technologies.Bio-Techne Corporation (NasdaqGS:TECH) completed the acquisition of Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others on July 10, 2023.공시 • Jun 23Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA.Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA on June 22, 2023. The transaction is expected to complete in first quarter of fiscal year 2024. Wenger Plattner acted as legal advisor to Bio-Techne. Bourgeois Avocat SA acted as legal advisor and UBS Investment Bank acted as financial advisor to Lunaphore Technologies.공시 • Jun 15PHC Holdings Corporation (TSE:6523) acquired remaining 30% stake in Scimed (Asia) Pte Ltd.PHC Holdings Corporation (TSE:6523) acquired remaining 30% stake in Scimed (Asia) Pte Ltd on June 15, 2023.PHC Holdings Corporation (TSE:6523) completed the acquisition of remaining 30% stake in Scimed (Asia) Pte Ltd on June 15, 2023.공시 • May 28PHC Holdings Corporation to Report Q1, 2024 Results on Aug 10, 2023PHC Holdings Corporation announced that they will report Q1, 2024 results on Aug 10, 2023공시 • May 13PHC Holdings Corporation, Annual General Meeting, Jun 23, 2023PHC Holdings Corporation, Annual General Meeting, Jun 23, 2023.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: PHCC.F 10년 미만 동안 배당금을 지급해 왔으며 이 기간 동안 지급액은 휘발성이었습니다.배당금 증가: PHCC.F 5 년 동안만 배당금을 지급해 왔으며 그 이후 지급액이 감소했습니다.배당 수익률 vs 시장PHC Holdings 배당 수익률 vs 시장PHCC.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PHCC.F)3.9%시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Medical Equipment)2.2%분석가 예측 (PHCC.F) (최대 3년)4.1%주목할만한 배당금: PHCC.F 의 배당금( 3.92% )은 US 시장에서 배당금 지급자의 하위 25%( 1.41% )보다 높습니다.고배당: PHCC.F 의 배당금( 3.92% )은 US 시장에서 배당금 지급자의 상위 25%( 4.24% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 지급 비율 ( 149.9% )이 높기 때문에 PHCC.F 의 배당금 지급은 수익으로 잘 충당되지 않습니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 15.9% )이 낮기 때문에 PHCC.F 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 11:54종가2026/03/30 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PHC Holdings Corporation는 10명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kei TakeuchiBofA Global ResearchHidemaru YamaguchiCitigroup IncAkinori UedaGoldman Sachs7명의 분석가 더 보기
공시 • Nov 12+ 1 more updatePHC Holdings Corporation Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2026, Payable on December 18, 2025PHC Holdings Corporation announced dividend for the second quarter end of the fiscal year ending March 31, 2026. For the period, the company announced dividend of JPY 21.00 per share against JPY 21.00 per share a year ago. Scheduled date to commence dividend payments: December 18, 2025.
공시 • May 14PHC Holdings Corporation, Annual General Meeting, Jun 24, 2026PHC Holdings Corporation, Annual General Meeting, Jun 24, 2026.
공시 • Apr 03PHC Holdings Corporation to Report Fiscal Year 2026 Results on May 13, 2026PHC Holdings Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 13, 2026
공시 • Jan 02Phc Holdings Corporation Announces Resignation of Koichiro Sato as Senior Executive Vice President, Representative Director and Chief Operating Officer, Effective January 2, 2026On December 31, 2025 (the “Execution Date”), Senseonics Holdings Inc. (the “Company”), Senseonics, Incorporated, a wholly-owned subsidiary of the Company (“Senseonics Inc.” and together with the Company, the “Purchaser Parties”) and Ascensia Diabetes Care Holdings AG (the “Seller”) entered into a master asset purchase agreement (the “Master Asset Purchase Agreement”), pursuant to which, among other things, the Purchaser Parties agreed to acquire Seller’s and as applicable, Seller’s affiliates’, right, title and interest in and to certain assets related Seller’s marketing, selling and distribution of the Eversense® product in the United States (such assets, the “U.S. Purchased Assets”). Pursuant to the terms of the Master Asset Purchase Agreement, the Purchaser Parties agreed to assume certain liabilities and obligations associated with the U.S. Purchased Assets (the “U.S. Assumed Liabilities” and together with the U.S. Purchased Assets, the “U.S. Asset Purchase”), including, but not limited to, certain liabilities under the contracts transferred to the Purchaser Parties under the Master Asset Purchase Agreement, liabilities arising out of the use or ownership of the transferred assets after the closing, and liabilities and obligations arising from certain employees whose employment is transferred to Senseonics Inc. pursuant to new employment letter agreements with Senseonics Inc. The U.S. Asset Purchase closed on January 1, 2026 (the “U.S. Closing”). On the Execution Date, in connection with the transactions described in Item 1.01 of this report, Koichiro Sato, Senior Executive Vice President, Representative Director and Chief Operating Officer of PHC Holdings Corporation, the parent company of the Seller, notified the board of directors (the “Board”) of the Company of his resignation from the Board effective immediately. Mr. Sato’s resignation is not due to any disagreements with the Company, management or Board on any matter relating to the Company’s operations, policies, or practices.
공시 • Dec 02PHC Holdings Corporation to Report Q3, 2026 Results on Feb 12, 2026PHC Holdings Corporation announced that they will report Q3, 2026 results on Feb 12, 2026
공시 • Nov 12+ 1 more updatePHC Holdings Corporation Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2026, Payable on December 18, 2025PHC Holdings Corporation announced dividend for the second quarter end of the fiscal year ending March 31, 2026. For the period, the company announced dividend of JPY 21.00 per share against JPY 21.00 per share a year ago. Scheduled date to commence dividend payments: December 18, 2025.
공시 • Sep 04PHC Holdings Corporation to Report Q2, 2026 Results on Nov 12, 2025PHC Holdings Corporation announced that they will report Q2, 2026 results on Nov 12, 2025
공시 • May 31PHC Holdings Corporation to Report Q1, 2026 Results on Aug 07, 2025PHC Holdings Corporation announced that they will report Q1, 2026 results on Aug 07, 2025
공시 • May 13PHC Holdings Corporation, Annual General Meeting, Jun 25, 2025PHC Holdings Corporation, Annual General Meeting, Jun 25, 2025.
공시 • Mar 07PHC Holdings Corporation to Report Fiscal Year 2025 Results on May 13, 2025PHC Holdings Corporation announced that they will report fiscal year 2025 results on May 13, 2025
공시 • Dec 06PHC Holdings Corporation to Report Q3, 2025 Results on Feb 12, 2025PHC Holdings Corporation announced that they will report Q3, 2025 results on Feb 12, 2025
공시 • Sep 04+ 1 more updatePHC Holdings Corporation to Report Q2, 2025 Results on Nov 13, 2024PHC Holdings Corporation announced that they will report Q2, 2025 results on Nov 13, 2024
공시 • Aug 30Phc Unveils Prototype of Licellgrow, New Cell Expansion System to Support Development of Cell and Gene Therapy Products Manufacturing ProcessPHC Corporation Biomedical Division will showcase a prototype of its new cell expansion system LiCellGrow at the ISCT (International Society for Cell & Gene Therapy) Europe 2024 Regional Meeting held in Gothenburg, Sweden on September 4-6. LiCellGrow, currently under development, is designed to allow pharmaceutical companies to visualize continuous metabolic changes in cells in real-time and adjust the cell culture automatically to optimize conditions for cell growth. The system seeks to expand availability of cell and gene therapy products by accelerating the manufacturing of specific cells needed for these therapies. CGT, in which a patient’s cells are removed, modified, and reintroduced to the body to fight disease, has emerged as a promising therapeutic field for difficult-to-treat conditions such as cancers and hematologic disorders. Since the patient’s own cells are used as raw materials, it is essential to maintain stable cell quality when producing new cells, to counteract natural variations in cell characteristics and ensure consistency throughout the therapy manufacturing process. The current method of evaluating cell quality by sampling the final product may lower both manufacturing efficiency and yield, increasing production cost. LiCellGrow seeks to enable more efficient and stable manufacture of high-quality CGT products by enabling researchers to monitor and control the cell culture environment in real time, optimizing cell quality while minimizing interruption to the therapy manufacturing process. The system under development uses proprietary In-Line monitoring technology, which continuously measures cell metabolites in the culture medium without the need for repeated sampling by immersing sensors in the medium at all times. LiCellGrow then continuously and accurately measures concentrations of two critical indicators of cell metabolism, glucose and lactate, to offer a visualization of actual changes in the culture environment and cell status. Based on real-time measurement data, the system then automatically exchanges the culture medium to maintain the culture environment in an optimal state. This technology is designed to improve and homogenize cell quality while increasing cell culture efficiency and reducing costs through loss reduction. The system will also feature easy-to-install single-use culture bags with In-Line sensors, enabling closed-system cell culturing to maintain a sterile environment, and can be installed in existing CO2 incubators, enabling researchers to conduct studies using their preferred equipment. LiCellGrow is an example of synergy between the Biomedical Division and IVD Division of PHC Corporation. The In-Line monitoring technology featured in this cell expansion system is newly developed proprietary technology building on the core technology of blood glucose sensor, the main product developed by IVD. By combining this sensor technology from IVD with advanced cell culture environment control technology from the Biomedical Division, PHC seeks to offer researchers and pharmaceutical companies greater value. The Biomedical Division plans to launch LiCellGrow to support the development of manufacturing processes for CGT products globally in the short term, and aims to accelerate development of this system to ultimately support commercialized production of CGT products. LiCellGrow builds on the Biomedical Division’s 20-year history of pioneering solutions in the field of cell therapy, including the Cell Processing Center in 2000 and the Cell Processing Isolator in 2007. Moving forward, they will continue to accelerate the creation of innovative solutions addressing QCD challenges in the therapeutic manufacturing process for early adoption of CGT, aiming to contribute to advancing modalities.
공시 • Jun 28PHC Holdings Corporation to Report Q1, 2025 Results on Aug 08, 2024PHC Holdings Corporation announced that they will report Q1, 2025 results on Aug 08, 2024
공시 • May 12PHC Holdings Corporation, Annual General Meeting, Jun 26, 2024PHC Holdings Corporation, Annual General Meeting, Jun 26, 2024.
공시 • Mar 09PHC Holdings Corporation to Report Fiscal Year 2024 Results on May 10, 2024PHC Holdings Corporation announced that they will report fiscal year 2024 results on May 10, 2024
공시 • Feb 13+ 1 more updatePHC Holdings Co., Ltd. Announces Management ChangesPHC Holdings Co. Ltd. has decided that Kyoko Deguchi will be appointed as the company's representative director and president on April 1, 2024. Masatsugu Miyazaki will step down from his duties as Representative director and president on March 31, and will continue to serve as a director until the general meeting of shareholders to be held in June. Mr. Deguchi, who is currently an independent director of the Company, has over 20 years of experience in the healthcare and chemical industries, and has previously served as head of the Japanese subsidiary of various global healthcare companies, including Janssen Pharmaceuticals, Stryker, and AbbVie. He has held senior positions in finance, marketing, etc. Currently, he is involved in management as the vice director of rehabilitation orthopedics, and has experience as an outside director at multiple listed and unlisted companies, including T-Gaia Co. Ltd. and Heartseed Co. Ltd.
공시 • Dec 09PHC Holdings Corporation to Report Q3, 2024 Results on Feb 09, 2024PHC Holdings Corporation announced that they will report Q3, 2024 results on Feb 09, 2024
공시 • Aug 30PHC Holdings Corporation to Report Q2, 2024 Results on Nov 10, 2023PHC Holdings Corporation announced that they will report Q2, 2024 results on Nov 10, 2023
공시 • Jul 11Bio-Techne Corporation (NasdaqGS:TECH) acquired Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others.Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others on June 22, 2023. The transaction is expected to complete in first quarter of fiscal year 2024. Wenger Plattner acted as legal advisor to Bio-Techne. Bourgeois Avocat SA acted as legal advisor and UBS Investment Bank acted as financial advisor to Lunaphore Technologies.Bio-Techne Corporation (NasdaqGS:TECH) completed the acquisition of Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others on July 10, 2023.
공시 • Jun 23Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA.Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA on June 22, 2023. The transaction is expected to complete in first quarter of fiscal year 2024. Wenger Plattner acted as legal advisor to Bio-Techne. Bourgeois Avocat SA acted as legal advisor and UBS Investment Bank acted as financial advisor to Lunaphore Technologies.
공시 • Jun 15PHC Holdings Corporation (TSE:6523) acquired remaining 30% stake in Scimed (Asia) Pte Ltd.PHC Holdings Corporation (TSE:6523) acquired remaining 30% stake in Scimed (Asia) Pte Ltd on June 15, 2023.PHC Holdings Corporation (TSE:6523) completed the acquisition of remaining 30% stake in Scimed (Asia) Pte Ltd on June 15, 2023.
공시 • May 28PHC Holdings Corporation to Report Q1, 2024 Results on Aug 10, 2023PHC Holdings Corporation announced that they will report Q1, 2024 results on Aug 10, 2023
공시 • May 13PHC Holdings Corporation, Annual General Meeting, Jun 23, 2023PHC Holdings Corporation, Annual General Meeting, Jun 23, 2023.